Details for New Drug Application (NDA): 011878
✉ Email this page to a colleague
NDA 011878 describes SERPASIL-ESIDRIX #2, which is a drug marketed by Novartis and is included in one NDA. Additional details are available on the SERPASIL-ESIDRIX #2 profile page.
The generic ingredient in SERPASIL-ESIDRIX #2 is hydrochlorothiazide; reserpine. There are thirty-two drug master file entries for this compound. Additional details are available on the hydrochlorothiazide; reserpine profile page.
The generic ingredient in SERPASIL-ESIDRIX #2 is hydrochlorothiazide; reserpine. There are thirty-two drug master file entries for this compound. Additional details are available on the hydrochlorothiazide; reserpine profile page.
Summary for 011878
| Tradename: | SERPASIL-ESIDRIX #2 |
| Applicant: | Novartis |
| Ingredient: | hydrochlorothiazide; reserpine |
| Patents: | 0 |
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 25MG;0.1MG | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Profile for product number 005
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 50MG;0.1MG | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
